{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:12:34Z","timestamp":1793747554208,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T00:00:00Z","timestamp":1586649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T00:00:00Z","timestamp":1586649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1038\/s41390-020-0863-0","type":"journal-article","created":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T11:02:12Z","timestamp":1586689332000},"page":"110-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The YAP signaling pathway promotes the progression of lymphatic malformations through the activation of lymphatic endothelial cells"],"prefix":"10.1038","volume":"89","author":[{"given":"Wenqun","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1218-2652","authenticated-orcid":false,"given":"Yu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,12]]},"reference":[{"key":"863_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jvs.2018.12.033","volume":"70","author":"A Fereydooni","year":"2019","unstructured":"Fereydooni, A., Dardik, A. & Nassiri, N. Molecular changes associated with vascular malformations. J. Vasc. Surg. 70, 314\u2013326. e311 (2019).","journal-title":"J. Vasc. Surg."},{"key":"863_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/SCS.0b013e3182413ea8","volume":"23","author":"AH Hassanein","year":"2012","unstructured":"Hassanein, A. H. et al. Lymphatic malformation: risk of progression during childhood and adolescence. J. Craniofac. Surg. 23, 149\u2013152 (2012).","journal-title":"J. Craniofac. Surg."},{"key":"863_CR3","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jpeds.2014.12.069","volume":"166","author":"VL Luks","year":"2015","unstructured":"Luks, V. L. et al. Lymphatic and other vascular malformative\/overgrowth disorders are caused by somatic mutations in PIK3CA. J. Pediatr. 166, 1048\u20131054. e1045 (2015).","journal-title":"J. Pediatr."},{"key":"863_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.humpath.2017.05.016","volume":"65","author":"JG Ren","year":"2017","unstructured":"Ren, J. G. et al. Down-regulation of polycystin in lymphatic malformations: possible role in the proliferation of lymphatic endothelial cells. Hum. Pathol. 65, 231\u2013238 (2017).","journal-title":"Hum. Pathol."},{"key":"863_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jvs.2010.07.019","volume":"53","author":"Y Yang","year":"2011","unstructured":"Yang, Y. et al. Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations. J. Vasc. Surg. 53, 150\u2013155 (2011).","journal-title":"J. Vasc. Surg."},{"key":"863_CR6","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nrm.2017.87","volume":"18","author":"T Panciera","year":"2017","unstructured":"Panciera, T. et al. Mechanobiology of YAP and TAZ in physiology and disease. Nat. Rev. Mol. Cell. Biol. 18, 758\u2013770 (2017).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"863_CR7","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1002\/hep.24587","volume":"54","author":"R Urtasun","year":"2011","unstructured":"Urtasun, R. et al. Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor\/yes-associated protein-mediated activation. Hepatology 54, 2149\u20132158 (2011).","journal-title":"Hepatology"},{"key":"863_CR8","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jpedsurg.2005.07.056","volume":"40","author":"MR Narkewicz","year":"2005","unstructured":"Narkewicz, M. R. et al. Connective tissue growth factor expression is increased in biliary epithelial cells in biliary atresia. J. Pediatr. Surg. 40, 1721\u20131725 (2005).","journal-title":"J. Pediatr. Surg."},{"key":"863_CR9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","volume":"163","author":"FX Yu","year":"2015","unstructured":"Yu, F. X., Zhao, B. & Guan, K. L. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163, 811\u2013828 (2015).","journal-title":"Cell"},{"key":"863_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1161\/CIRCRESAHA.118.313707","volume":"124","author":"H Cho","year":"2019","unstructured":"Cho, H. et al. YAP and TAZ negatively regulate Prox1 during developmental and pathologic lymphangiogenesis. Circ. Res. 124, 225\u2013242 (2019).","journal-title":"Circ. Res."},{"key":"863_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/all.13647","volume":"74","author":"H Deng","year":"2018","unstructured":"Deng, H. et al. The hippo pathway effector Yes\u2010associated protein promotes epithelial proliferation and remodeling in chronic rhinosinusitis with nasal polyps. Allergy 74, 731\u2013742 (2018).","journal-title":"Allergy"},{"key":"863_CR12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.surg.2015.12.008","volume":"159","author":"L Yi","year":"2016","unstructured":"Yi, L. et al. Yes-associated protein (YAP) signaling regulates lipopolysaccharide-induced tissue factor expression in human endothelial cells. Surgery 159, 1436\u20131448 (2016).","journal-title":"Surgery"},{"key":"863_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.prp.2010.08.001","volume":"206","author":"Y Cai","year":"2010","unstructured":"Cai, Y. et al. Expression of Neuropilin-2 in salivary adenoid cystic carcinoma: its implication in tumor progression and angiogenesis. Pathol. Res. Pract. 206, 793\u2013799 (2010).","journal-title":"Pathol. Res. Pract."},{"key":"863_CR14","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1016\/j.ajpath.2017.07.019","volume":"187","author":"JG Yang","year":"2017","unstructured":"Yang, J. G. et al. Lymphotoxins promote the progression of human lymphatic malformation by enhancing lymphatic endothelial cell proliferation. Am. J. Pathol. 187, 2602\u20132615 (2017).","journal-title":"Am. J. Pathol."},{"key":"863_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1203\/PDR.0b013e3181bf572b","volume":"67","author":"J Jia","year":"2010","unstructured":"Jia, J. et al. Overexpression of allograft inflammatory factor-1 promotes the proliferation and migration of human endothelial cells (HUV-EC-C) probably by up-regulation of basic fibroblast growth factor. Pediatr. Res. 67, 29\u201334 (2010).","journal-title":"Pediatr. Res."},{"key":"863_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0002-9440(10)65285-6","volume":"154","author":"S Breiteneder-Geleff","year":"1999","unstructured":"Breiteneder-Geleff, S. et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 154, 385\u2013394 (1999).","journal-title":"Am. J. Pathol."},{"key":"863_CR17","first-page":"167","volume":"7","author":"C Alexander","year":"2001","unstructured":"Alexander, C. & Rietschel, E. T. Bacterial lipopolysaccharides and innate immunity. J. Endotoxin Res. 7, 167\u2013202 (2001).","journal-title":"J. Endotoxin Res."},{"key":"863_CR18","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1016\/j.febslet.2013.10.042","volume":"587","author":"L Li","year":"2013","unstructured":"Li, L. et al. MEK1 promotes YAP their interaction is critical for tumorigenesis in liver cancer. FEBS Lett. 587, 3921\u20133927 (2013).","journal-title":"FEBS Lett."},{"key":"863_CR19","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-16-0155","volume":"76","author":"T Muranen","year":"2016","unstructured":"Muranen, T. et al. ERK and p38 MAPK activities determine sensitivity to PI3K\/mTOR inhibition via regulation of MYC and YAP. Cancer Res. 76, 7168\u20137180 (2016).","journal-title":"Cancer Res."},{"key":"863_CR20","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.18632\/oncotarget.2974","volume":"6","author":"B You","year":"2015","unstructured":"You, B. et al. Inhibition of ERK1\/2 down-regulates the Hippo\/YAP signaling pathway in human NSCLC cells. Oncotarget 6, 4357\u20134368 (2015).","journal-title":"Oncotarget"},{"key":"863_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/j.sempedsurg.2006.02.011","volume":"15","author":"RG Elluru","year":"2006","unstructured":"Elluru, R. G. & Azizkhan, R. G. Cervicofacial vascular anomalies. II. Vascular malformations. Semin. Pediatr. Surg. 15, 133\u2013139 (2006).","journal-title":"Semin. Pediatr. Surg."},{"key":"863_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/archfacial.2011.795","volume":"13","author":"M Hochman","year":"2011","unstructured":"Hochman, M., Adams, D. M. & Reeves, T. D. Current knowledge and management of vascular anomalies, II: malformations. Arch. Facial Plast. Surg. 13, 425\u2013433 (2011).","journal-title":"Arch. Facial Plast. Surg."},{"key":"863_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/bjophthalmol-2013-303887","volume":"98","author":"F Bucher","year":"2014","unstructured":"Bucher, F. et al. Regression of mature lymphatic vessels in the cornea by photodynamic therapy. Br. J. Ophthalmol. 98, 391\u2013395 (2014).","journal-title":"Br. J. Ophthalmol."},{"key":"863_CR24","doi-asserted-by":"publisher","first-page":"69ra11","DOI":"10.1126\/scitranslmed.3001699","volume":"3","author":"T Tammela","year":"2011","unstructured":"Tammela, T. et al. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci. Transl. Med. 3, 69ra11 (2011).","journal-title":"Sci. Transl. Med."},{"key":"863_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04590-1","volume":"9","author":"D Martin","year":"2018","unstructured":"Martin, D. et al. Assembly and activation of the Hippo signalome by FAT1 tumor suppressor. Nat. Commun. 9, 2372 (2018).","journal-title":"Nat. Commun."},{"key":"863_CR26","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","volume":"20","author":"A Totaro","year":"2018","unstructured":"Totaro, A., Panciera, T. & Piccolo, S. YAP\/TAZ upstream signals and downstream responses. Nat. Cell Biol. 20, 888\u2013899 (2018).","journal-title":"Nat. Cell Biol."},{"key":"863_CR27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1242\/jcs.137836","volume":"127","author":"T Ichise","year":"2014","unstructured":"Ichise, T., Yoshida, N. & Ichise, H. FGF2-induced Ras-MAPK signalling maintains lymphatic endothelial cell identity by upregulating endothelial-cell-specific gene expression and suppressing TGFbeta signalling through Smad2. J. Cell Sci. 127, 845\u2013857 (2014).","journal-title":"J. Cell Sci."},{"key":"863_CR28","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/ecco-jcc\/jjy046","volume":"12","author":"M Yu","year":"2018","unstructured":"Yu, M. et al. MicroRNA-590-5p inhibits intestinal inflammation by targeting YAP. J. Crohns Colitis 12, 993\u20131004 (2018).","journal-title":"J. Crohns Colitis"},{"key":"863_CR29","doi-asserted-by":"publisher","first-page":"11230","DOI":"10.1074\/jbc.RA118.002715","volume":"293","author":"SW Plouffe","year":"2018","unstructured":"Plouffe, S. W. et al. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell. J. Biol. Chem. 293, 11230\u201311240 (2018).","journal-title":"J. Biol. Chem."},{"key":"863_CR30","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/stem.2652","volume":"35","author":"C Sun","year":"2017","unstructured":"Sun, C. et al. Common and distinctive functions of the Hippo effectors Taz and Yap in skeletal muscle stem cell function. Stem Cells 35, 1958\u20131972 (2017).","journal-title":"Stem Cells"},{"key":"863_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrc3876","volume":"15","author":"T Moroishi","year":"2015","unstructured":"Moroishi, T., Hansen, C. G. & Guan, K. L. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 15, 73\u201379 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"863_CR32","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1084\/jem.20140341","volume":"211","author":"N Liang","year":"2014","unstructured":"Liang, N. et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J. Exp. Med. 211, 2249\u20132263 (2014).","journal-title":"J. Exp. Med."},{"key":"863_CR33","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1073\/pnas.1216462110","volume":"110","author":"R Fan","year":"2013","unstructured":"Fan, R., Kim, N. G. & Gumbiner, B. M. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc. Natl Acad. Sci. USA 110, 2569\u20132574 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"863_CR34","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2015.07.013","volume":"162","author":"HW Park","year":"2015","unstructured":"Park, H. W. et al. Alternative Wnt signaling activates YAP\/TAZ. Cell 162, 780\u2013794 (2015).","journal-title":"Cell"},{"key":"863_CR35","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2012.06.037","volume":"150","author":"FX Yu","year":"2012","unstructured":"Yu, F. X. et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150, 780\u2013791 (2012).","journal-title":"Cell"},{"key":"863_CR36","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3892\/or.2012.2176","volume":"29","author":"X Huo","year":"2013","unstructured":"Huo, X. et al. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma. Oncol. Rep. 29, 840\u2013846 (2013).","journal-title":"Oncol. Rep."},{"key":"863_CR37","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.biopha.2018.06.031","volume":"105","author":"T Lu","year":"2018","unstructured":"Lu, T., Sun, L. & Zhu, X. Yes-associated protein enhances proliferation and attenuates sensitivity to cisplatin in human gastric cancer cells. Biomed. Pharmacother. 105, 1269\u20131275 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"863_CR38","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/biomedicines6040114","volume":"6","author":"PC Hsu","year":"2018","unstructured":"Hsu, P. C. et al. The role of Yes-associated protein (YAP) in regulating programmed death-ligand 1 (PD-L1) in thoracic cancer. Biomedicines 6, 114 (2018)","journal-title":"Biomedicines"},{"key":"863_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrd4161","volume":"13","author":"R Johnson","year":"2014","unstructured":"Johnson, R. & Halder, G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat. Rev. Drug Discov. 13, 63\u201379 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"863_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ophtha.2005.09.002","volume":"113","author":"AJ Augustin","year":"2006","unstructured":"Augustin, A. J. & Schmidt-Erfurth, U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113, 14\u201322 (2006).","journal-title":"Ophthalmology"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41390-020-0863-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-020-0863-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-020-0863-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:30:49Z","timestamp":1684618249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-020-0863-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1038\/s41390-020-0863-0","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,12]]},"assertion":[{"value":"20 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients signed informed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}